Shifting Paradigms in Neovascular Retinal Disease: Novel Ways to Address Anti-VEGF Injection Burden and Insufficient Response is organized by Healio.
Release Date: 8/30/23
Expiration Date: 8/30/24
Program Overview
Compared with anti-vascular endothelial growth factor (VEGF) inhibition, dual pathway inhibition (angiopoietin/Tie2 and vascular endothelial growth factor [VEGF]-A) with novel therapy offers the potential for visual and anatomic improvement with fewer injections in patients with neovascular retinal diseases. What are the benefits and risks of novel therapy? Which patients are ideal candidates? What are the good parameters for extending, maintaining, or shortening dosing intervals? Join internationally renowned experts as they answer these questions and more using real-life case studies and the best available evidence.
Learning Objective
Upon completion of this activity, participants should be able to:
• Recognize potential causes of the limitations of conventional intravitreal anti-VEGF therapy that may be addressed with novel therapy
• Compare clinical characteristics of novel therapy with conventional anti-VEGF, including efficacy, safety, and durability
• Develop individualized treatment plans for patients with neovascular retinal diseases that demonstrate the role of novel therapy, including appropriate patient selection and dosing frequency